JP2008507282A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008507282A5 JP2008507282A5 JP2007522752A JP2007522752A JP2008507282A5 JP 2008507282 A5 JP2008507282 A5 JP 2008507282A5 JP 2007522752 A JP2007522752 A JP 2007522752A JP 2007522752 A JP2007522752 A JP 2007522752A JP 2008507282 A5 JP2008507282 A5 JP 2008507282A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic composition
- autoantigen
- expression vector
- polypeptide
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58970704P | 2004-07-20 | 2004-07-20 | |
| US61452904P | 2004-09-29 | 2004-09-29 | |
| PCT/US2005/025878 WO2006012416A2 (en) | 2004-07-20 | 2005-07-20 | Specific inhibition of autoimmunity and diseases associated with autoantigens |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008507282A JP2008507282A (ja) | 2008-03-13 |
| JP2008507282A5 true JP2008507282A5 (cg-RX-API-DMAC7.html) | 2009-04-02 |
Family
ID=35786697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007522752A Pending JP2008507282A (ja) | 2004-07-20 | 2005-07-20 | 自己免疫および自己抗原に関連する疾患の特異的阻害 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20090053249A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1778296B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2008507282A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101068574B (cg-RX-API-DMAC7.html) |
| CA (1) | CA2574802A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL180817A0 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006012416A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1616016B1 (en) * | 2003-03-19 | 2012-11-14 | Isogenis, Inc. | Gene therapy vectors having reduced immunogenicity based on cd8 alpha-chain |
| EP2020240A1 (en) * | 2007-07-30 | 2009-02-04 | Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe | Methods and substances for the treatment of Alzheimer's |
| EP2342321B1 (en) * | 2008-09-17 | 2018-04-11 | Isogenis, Inc. | Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof |
| US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| AU2011289579B2 (en) * | 2010-08-10 | 2016-11-17 | Ecole Polytechnique Federale De Lausanne | Erythrocyte-binding therapeutics |
| US9848587B2 (en) * | 2013-02-20 | 2017-12-26 | Regeneron Pharmaceuticals, Inc. | Humanized T cell co-receptor mice |
| KR102181336B1 (ko) | 2013-06-13 | 2020-11-24 | 오르제네시스 엘티디. | 세포 집단, 이의 전환분화 방법 및 이용 방법 |
| US20160158352A1 (en) * | 2013-07-10 | 2016-06-09 | The United States of America, as represented by the Secretary, Department of Health & Human Servic | Apoptotic cell-mediated induction of antigen specific regulatory t-cells for the therapy of autoimmune diseases in animals and humans |
| CN106456744A (zh) | 2014-04-01 | 2017-02-22 | 鲁比厄斯治疗法股份有限公司 | 用于免疫调节的方法和组合物 |
| US11123404B2 (en) | 2016-01-07 | 2021-09-21 | B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University | Methods for generating immunotolerant responses |
| WO2018207179A1 (en) | 2017-05-08 | 2018-11-15 | Orgenesis Ltd. | Transdifferentiated cell populations and methods of use thereof |
| AU2018338786A1 (en) * | 2017-09-29 | 2020-04-16 | Nantcell, Inc. | Antigenic proteins and methods therefor |
| US12583894B2 (en) * | 2018-04-04 | 2026-03-24 | University Of Florida Research Foundation, Incorporated | Materials and methods for the treatment of Lewy body disorders |
| AU2019256536C1 (en) | 2018-04-19 | 2026-01-15 | Baylor College Of Medicine | Reprogramming CD4 T cells into cytotoxic CD8 cells by forced expression of CD8αβ and Class 1 restricted T cell receptors |
| US12234473B2 (en) | 2020-12-31 | 2025-02-25 | Immatics US, Inc. | CD8 polypeptides, compositions, and methods of using thereof |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5078998A (en) * | 1985-08-02 | 1992-01-07 | Bevan Michael J | Hybrid ligand directed to activation of cytotoxic effector T lymphocytes and target associated antigen |
| US6048729A (en) * | 1987-05-01 | 2000-04-11 | Transkaryotic Therapies, Inc. | In vivo protein production and delivery system for gene therapy |
| US5242687A (en) * | 1989-03-15 | 1993-09-07 | Tkb Associates Limited Partnership | Method of reducing cellular immune response involving T-cells using CD8-bearing antigen presenting cells |
| JPH04506061A (ja) * | 1989-03-15 | 1992-10-22 | タイコシンスキー,マーク エル. | Cd8に基づく製剤 |
| US5601828A (en) * | 1989-03-15 | 1997-02-11 | Tkb Associates Limited Partnership | CD8 derivatives and methods of use for cellular modulation and enhancement of cellular engraftment |
| US5672346A (en) | 1992-07-27 | 1997-09-30 | Indiana University Foundation | Human stem cell compositions and methods |
| US5540926A (en) * | 1992-09-04 | 1996-07-30 | Bristol-Myers Squibb Company | Soluble and its use in B cell stimulation |
| ES2072223B1 (es) | 1993-11-25 | 1996-03-16 | Lipotec Sa | Liposomas encapsulando doxorubicina. |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US5851806A (en) * | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
| US6143292A (en) | 1995-05-25 | 2000-11-07 | Baxter International Inc. | Allogeneic cell therapy for cancer following allogeneic stem cell transplantation |
| IL115199A (en) * | 1995-09-07 | 2005-05-17 | Opperbas Holding Bv | Composition comprising a polynucleic acid molecule in a liposome and method using said composition |
| GB9524973D0 (en) * | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| US5939250A (en) | 1995-12-07 | 1999-08-17 | Diversa Corporation | Production of enzymes having desired activities by mutagenesis |
| US5830696A (en) | 1996-12-05 | 1998-11-03 | Diversa Corporation | Directed evolution of thermophilic enzymes |
| US5965408A (en) | 1996-07-09 | 1999-10-12 | Diversa Corporation | Method of DNA reassembly by interrupting synthesis |
| WO1997025446A1 (en) * | 1996-01-05 | 1997-07-17 | Genetic Therapy, Inc. | Recombinase-mediated generation of adenoviral vectors |
| US6734014B1 (en) | 1996-02-08 | 2004-05-11 | The United States Of America As Represented By The Department Of Health And Human Services | Methods and compositions for transforming dendritic cells and activating T cells |
| US5952221A (en) | 1996-03-06 | 1999-09-14 | Avigen, Inc. | Adeno-associated virus vectors comprising a first and second nucleic acid sequence |
| US6228646B1 (en) | 1996-03-07 | 2001-05-08 | The Regents Of The University Of California | Helper-free, totally defective adenovirus for gene therapy |
| US6060054A (en) * | 1996-04-10 | 2000-05-09 | National Jewish Medical And Research Center | Product for T lymphocyte immunosuppression |
| US5763239A (en) | 1996-06-18 | 1998-06-09 | Diversa Corporation | Production and use of normalized DNA libraries |
| US6211342B1 (en) | 1996-07-18 | 2001-04-03 | Children's Hospital Medical Center | Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function |
| BR9713498A (pt) * | 1996-11-08 | 2000-02-29 | Idec Pharma Corp | Identificação de interações de ligação singulares entre alguns anticorpos e os antìgenos co-estimulatórios b7.1 e b7.2 humanos |
| US5873458A (en) | 1997-09-12 | 1999-02-23 | Kao; Kuo-Min | Drawer type CD box structure |
| GB9722779D0 (en) * | 1997-10-28 | 1997-12-24 | Isis Innovation | Human CD8 as an inhibitor of the cellular immune system |
| EP1025242A1 (en) * | 1997-10-30 | 2000-08-09 | Cornell Research Foundation, Inc. | A method of inhibiting an immune response to a recombinant vector |
| AU3456099A (en) | 1998-03-31 | 1999-10-18 | Geron Corporation | Methods and compositions for eliciting an immune response to a telomerase antigen |
| US5945325A (en) | 1998-04-20 | 1999-08-31 | California Institute Of Technology | Thermally stable para-nitrobenzyl esterases |
| US20020127205A1 (en) * | 1998-08-31 | 2002-09-12 | Albert Edge | Cells expressing immunoregulatory molecules and uses therefor |
| US6509150B1 (en) * | 1999-03-05 | 2003-01-21 | Universite De Nantes | Compositions and methods for recombinant Adeno-Associated Virus production |
| GB9906177D0 (en) | 1999-03-17 | 1999-05-12 | Oxford Biomedica Ltd | Anti-viral vectors |
| JP2002541845A (ja) * | 1999-04-16 | 2002-12-10 | セルテック セラピューティックス リミテッド | 合成膜貫通成分 |
| US6544506B2 (en) * | 2000-01-05 | 2003-04-08 | Yeda Research & Development Co. Ltd. | Veto cells effective in preventing graft rejection and devoid of graft versus host potential |
| US6762031B2 (en) | 2000-06-16 | 2004-07-13 | University Of Medicine And Dentistry Of New Jersey | Targeting viral vectors to specific cells |
| US6534052B1 (en) | 2000-09-05 | 2003-03-18 | Yong-Fu Xiao | Cardiac function comprising implantation of embryonic stem cell in which differentiation has been initiated |
| WO2002022212A2 (en) * | 2000-09-18 | 2002-03-21 | Idec Pharmaceuticals Corporation | Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| US7235358B2 (en) * | 2001-06-08 | 2007-06-26 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
| US7026121B1 (en) * | 2001-06-08 | 2006-04-11 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
| GB0114533D0 (en) | 2001-06-14 | 2001-08-08 | Avidex Ltd | Substances |
| EP1616016B1 (en) * | 2003-03-19 | 2012-11-14 | Isogenis, Inc. | Gene therapy vectors having reduced immunogenicity based on cd8 alpha-chain |
| US9701019B2 (en) | 2011-09-15 | 2017-07-11 | Convergent Information Technologies Gmbh | System and method for the automatic generation of robot programs |
| ES2741897T3 (es) | 2012-02-13 | 2020-02-12 | Radius Eng Inc | Cartucho reutilizable para moldeo por inyección |
-
2005
- 2005-07-20 CA CA002574802A patent/CA2574802A1/en not_active Abandoned
- 2005-07-20 EP EP05790332A patent/EP1778296B1/en not_active Expired - Lifetime
- 2005-07-20 JP JP2007522752A patent/JP2008507282A/ja active Pending
- 2005-07-20 CN CN2005800317082A patent/CN101068574B/zh not_active Expired - Fee Related
- 2005-07-20 WO PCT/US2005/025878 patent/WO2006012416A2/en not_active Ceased
- 2005-07-20 US US11/572,259 patent/US20090053249A1/en not_active Abandoned
-
2007
- 2007-01-18 IL IL180817A patent/IL180817A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Burgess et al. | Narcolepsy: neural mechanisms of sleepiness and cataplexy | |
| Goverman | Immune tolerance in multiple sclerosis | |
| Schneeberger et al. | Active immunization therapies for Parkinson's disease and multiple system atrophy | |
| Farina et al. | Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action | |
| Sospedra et al. | Immunology of multiple sclerosis | |
| Anderton et al. | Hierarchy in the ability of T cell epitopes to induce peripheral tolerance to antigens from myelin | |
| Candia et al. | On peptides and altered peptide ligands: from origin, mode of action and design to clinical application (immunotherapy) | |
| Waksman | Immune regulation in adjuvant disease and other arthritis models: relevance to pathogenesis of chronic arthritis | |
| McCombe et al. | Sex differences in Guillain Barré syndrome, chronic inflammatory demyelinating polyradiculoneuropathy and experimental autoimmune neuritis | |
| Villoslada et al. | Frequency, heterogeneity and encephalitogenicity of T cells specific for myelin oligodendrocyte glycoprotein in naive outbred primates | |
| Anderton | Peptide-based immunotherapy of autoimmunity: a path of puzzles, paradoxes and possibilities | |
| Prat et al. | The immunopathogenesis of multiple sclerosis. | |
| JP2020510698A5 (cg-RX-API-DMAC7.html) | ||
| Vaitaitis et al. | CD 40‐mediated signalling influences trafficking, T‐cell receptor expression, and T‐cell pathogenesis, in the NOD model of type 1 diabetes | |
| Sospedra et al. | Antigen-specific therapies in multiple sclerosis | |
| JP2024116146A (ja) | 多発性硬化症における免疫優性タンパク質および断片 | |
| Falk et al. | Induction and suppression of an autoimmune disease by oligomerized T cell epitopes: enhanced in vivo potency of encephalitogenic peptides | |
| Ben‐Nun et al. | Anatomy of T cell autoimmunity to myelin oligodendrocyte glycoprotein (MOG): Prime role of MOG44F in selection and control of MOG‐reactive T cells in H‐2b mice | |
| Campos et al. | Interleukin‐4‐dependent innate collaboration between iNKT cells and B‐1 B cells controls adaptative contact sensitivity | |
| Fridkis-Hareli | Design of Peptide Immunotherapies for MHC Class‐II‐Associated Autoimmune Disorders | |
| JP2016513963A5 (cg-RX-API-DMAC7.html) | ||
| Monneaux et al. | Intramolecular T cell spreading in unprimed MRL/lpr mice: Importance of the U1‐70k protein sequence 131–151 | |
| Kaushansky et al. | ‘Multi-epitope-targeted’immune-specific therapy for a multiple sclerosis-like disease via engineered multi-epitope protein is superior to peptides | |
| Furuzawa-Carballeda et al. | Polymerized‐type I collagen induces upregulation of Foxp3‐expressing CD4 regulatory T cells and downregulation of IL‐17‐producing CD4+ T cells (Th17) cells in collagen‐induced arthritis | |
| Stüve et al. | DNA-based vaccines: the future of multiple sclerosis therapy? |